— Know what they know.
Not Investment Advice

Financial News

Sentiment -66.1 4867 articles 2319 bullish 1373 bearish Full Index →
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Ob

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week E

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
COR to Expand Retina Consultants of America With $1.1B EyeSo

COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care...
Cardinal Health vs. McKesson: Which Healthcare Giant Is the

Cardinal Health vs. McKesson: Which Healthcare Giant Is the Smarter Bet?

CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.
ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt

ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt in 2026?

ISRG records 37% margins despite tariff pressure, using cost efficiencies and recurring revenue strength to offset headwinds and sustain...
ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt

ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt in 2026?

ISRG records 37% margins despite tariff pressure, using cost efficiencies and recurring revenue strength to offset headwinds and sustain...
Cardinal Health vs. McKesson: Which Healthcare Giant Is the

Cardinal Health vs. McKesson: Which Healthcare Giant Is the Smarter Bet?

CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.
ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt

ISRG's Margins Contract in Q4: Will Tariffs Continue to Hurt in 2026?

ISRG records 37% margins despite tariff pressure, using cost efficiencies and recurring revenue strength to offset headwinds and sustain...
📰

Why Lenz Therapeutics Stock Crashed Today

Is it time to throw away your reading glasses? Maybe not just yet.
Ownwell and Carrington Mortgage Services, LLC Partner to Low

Ownwell and Carrington Mortgage Services, LLC Partner to Lower Homeowner Property Taxes

Property tax technology leader joins forces with top-tier mortgage servicer to help homeowners save AUSTIN, Texas, March 24, 2026 /PRNewswire/ --...
Advanced Cell-based Therapy Booming the Success for Healthca

Advanced Cell-based Therapy Booming the Success for Healthcare Sector

Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /PRNewswire/ -- USANewsGroup.com — The FDA has approved more than 40 cell and gene...
📰

Inman, a leading source of real estate news, events, and intelligenceAppoints Tom Bohn as Chief Executive Officer

TALLAHASSEE, Fla., March 24, 2026 /PRNewswire-PRWeb/ -- Inman, a leading source of real estate news, events, and intelligence, announced the...
Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Result

Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 350 points on Tuesday. Following the market opening Tuesday, the...
Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Result

Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 350 points on Tuesday. Following the market opening Tuesday, the...
Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Result

Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 350 points on Tuesday. Following the market opening Tuesday, the...
Wall Street Analysts Predict a 51.12% Upside in OrthoPediatr

Wall Street Analysts Predict a 51.12% Upside in OrthoPediatrics (KIDS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 51.1% in OrthoPediatrics (KIDS). While the effectiveness of...
Wall Street Analysts Predict an 182.79% Upside in Assertio (

Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 182.8% in Assertio (ASRT). While the effectiveness of this...
Here's Why Inovio (INO) Looks Ripe for Bottom Fishing

Here's Why Inovio (INO) Looks Ripe for Bottom Fishing

Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward...
Move & Connect geht eine Partnerschaft mit KORE ein, um

Move & Connect geht eine Partnerschaft mit KORE ein, um nahtlose europaweite IoT-Konnektivität für kritische Branchen bereitzustellen

ATLANTA, 24. März 2026 /PRNewswire/ -- KORE Group Holdings, Inc. (NYSE: KORE), der globale Hyperscaler im Bereich des Internets der Dinge („IoT") und...
Move & Connect se asocia con KORE para ofrecer conectivi

Move & Connect se asocia con KORE para ofrecer conectividad IoT

- Move & Connect se asocia con KORE para ofrecer conectividad IoT paneuropea sin interrupciones para industrias críticas ATLANTA, 24 de marzo de 2026...
📰

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative,...
📰

Here's Why Illumina (ILMN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks...
📰

The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant

Eli Lilly, RTX, Abbott, Ohio Valley Banc, and Rave Restaurant make Zacks' daily analyst blog with fresh insights on growth and market trends.
📰

The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant

Eli Lilly, RTX, Abbott, Ohio Valley Banc, and Rave Restaurant make Zacks' daily analyst blog with fresh insights on growth and market trends.
📰

Fresenius (FMS) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks...
📰

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
📰

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
📰

Why Encompass Health (EHC) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks...
📰

Zoetis (ZTS) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What's Going On With Palantir Shares On Tuesday?

What's Going On With Palantir Shares On Tuesday?

Palantir Technologies (NASDAQ:PLTR) shares are trading lower during Tuesday’s premarket session as risk appetite softens across equities and...
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong...
What's Going On With Ridgetech Shares On Tuesday?

What's Going On With Ridgetech Shares On Tuesday?

Ridgetech (NASDAQ:RDGT) shares are down during Tuesday’s premarket session. This month, the company disclosed its 2026 dual-engine growth...
Wall Street Bulls Look Optimistic About CVS Health (CVS): Sh

Wall Street Bulls Look Optimistic About CVS Health (CVS): Should You Buy?

The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts...
Brokers Suggest Investing in Johnson & Johnson (JNJ): Read T

Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet

The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street...
« Prev 1 46 47 48 49 50 82 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms